Stomach bug battle: new drug combo could beat tough infections
NCT ID NCT06349486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests three different 14-day treatments for H. pylori, a bacteria that can cause stomach ulcers and cancer. About 390 infected adults will receive either a new triple therapy with bismuth, a dual therapy, or a standard treatment. The goal is to see which works best and how antibiotic resistance affects success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI ERADICATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaohsiung Medical University Hospital
RECRUITINGKaohsiung City, 807, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a closer look at the stomach spot hidden infections?
- Which antibiotic combo wins against h. pylori? a Head-to-Head test
- Can customizing antibiotics beat stomach bug resistance?
- A supplement may tame the Gut-Wrenching side effects of h. pylori therapy
- Could a fecal transplant beat a stubborn stomach bug?
- AI eye on stomach cancer: 6,000-Person trial tests smarter scopes